ADD/ADHD News

Researchers estimated that 6%, or one in 16, U.S. adults had an ADHD diagnosis, more than half of whom were diagnosed in adulthood, according to findings published in the CDC’s Morbidity and Mortality Weekly Report.

The combined use of selective serotonin reuptake inhibitors and methylphenidate did not significantly increase adverse event risk among adults with ADHD and comorbid depression, according to a study published in JAMA Network Open.

Patients with past-month exposure to prescription amphetamines used to treat ADHD had higher odds of developing psychosis or mania compared with those without past-month exposure, according to a recent study.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

Many factors have contributed to the recent surge in adult ADHD diagnoses, but the rise is mostly reflective of what has always existed and gone undetected, according to experts.

The FDA has approved Onyda XR extended-release oral suspension for the treatment of ADHD among children aged 6 years and older, according to a press release from Tris Pharma, Inc.

Approximately one in nine children in the United States had ever received an ADHD diagnosis as of 2022, according to research published in the Journal of Clinical Child & Adolescent Psychology.

However, the prevalence of cardiomyopathy in this population was less than 1%.

A systematic review of hundreds of studies showed that medication has the best chance to improve ADHD outcomes in children and that other treatments have varied effects, according to results published in Pediatrics.